ArticleInflammopharmacology2025
Anti-inflammatory and gastroprotective effects of Fagonia bruguieri var. laxa (Zygophyllaceae) via attenuating biochemical alterations and cellular damage in experimental animals.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe current study aims to authenticate the traditional usage of Fagonia bruguieri var. laxa in eczema, ulcers, and gastrointestinal diseases.
methodsFagonia bruguieri var. laxa. was collected, washed, dried, and ground, and its 70% aqueous methanolic solution was subjected to a rotary evaporator to produce the crude extract of the plant. Preliminary phytochemical screening was performed to validate the presence of secondary metabolites. The anti-inflammatory potential was assessed using the Carrageenan-induced paw edema test, and the anti-peptic ulcer activity was assessed using the Aspirin-induced gastric lesion/ulcer and Cysteamine-induced duodenal lesion/ulcer models in Wistar albino rats. At the end of the experiment, total acidity, ulcer index, biochemical markers, and histological changes were assessed.
resultThe crude extract of Fagonia bruguieri var. laxa. (Fb.Cr) reduced rat paw edema significantly (P < 0.001) by the fifth hour, with a maximum percent inhibition of 30.6%. In an aspirin-induced gastric lesion model, Fb.Cr was observed to improve pH, decrease overall acidity of stomach contents, and reduce ulcer index at dosages ranging from 100 to 500 mg/kg. In the Cysteamine-induced duodenal lesion model, Fb.Cr was found to reduce the severity score and ulcer index in a dose-dependent manner. The acute toxicity investigation determined that crude extract was safe up to the dose of 5 g/kg.
conclusionThe current study's findings show that the crude extract of Fagonia bruguieri (Fb.Cr) has anti-inflammatory, gastric, and duodenal protective actions, which support its folkloric use in the management and treatment of inflammation and gastric disorders.
Indexed as
Identifiers
40622466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.